Abstracts tagged "Administrative Data"

Abstract Number: 0318 • ACR Convergence 2022
Development and Validation of Algorithms to Identify Cutaneous Lupus Patients Using Diagnostic Codes and Prescription Data
Lisa Guo¹, Jordan Said², Vinod Nambudiri³ and Joseph Merola³, ¹Brigham and Women's Hospital, Boston, MA, ²Harvard Medical School, Boston, MA, ³Harvard Medical School, Brigham and Women's Hospital, Boston, MA
Background/Purpose: There is a paucity of epidemiological studies of cutaneous lupus erythematosus (CLE), which may be due in part to the lack of well-validated methods…
Abstract Number: 1189 • ACR Convergence 2022
Natural Language Processing of Chest CT Reports as a Novel Method of Identifying RA-ILD in Real-World Data
Brent Luedders¹, Punyasha Roul², Yangyuna Yang¹, Brendan Cope¹, Matt DeVries¹, W. Scott Campbell¹, Daniel Hershberger¹, Jorge Rojas³, Grant Cannon⁴, Brian Sauer⁵, Joshua Baker⁶, Jeffrey Curtis⁷, Ted Mikuls⁸ and Bryant England¹, ¹University of Nebraska Medical Center, Omaha, NE, ²UNMC, Omaha, NE, ³George E. Wahlen Department of Veterans Affairs Salt Lake City Health Care System, Salt Lake City, UT, ⁴Retired, Salt Lake City, UT, ⁵Salt Lake City VA/University of Utah, Salt Lake City, UT, ⁶University of Pennsylvania, Philadelphia, PA, ⁷University of Alabama at Birmingham, Hoover, AL, ⁸Division of Rheumatology, University of Nebraska Medical Center, Omaha, NE
Background/Purpose: Algorithms incorporating diagnostic and procedural codes have recently been developed to identify rheumatoid arthritis-associated interstitial lung disease (RA-ILD) in administrative and electronic health record…
Abstract Number: 0347 • ACR Convergence 2022
Real-World Effectiveness of Belimumab in Patients with SLE in the United States
Christopher Bell¹, Bernie Rubin², Karen Worley³, Guillaume Germain⁴, François Laliberté⁴, Sean D. MacKnight⁴, Ana Urosevic⁴ and Mei Sheng Duh⁵, ¹GlaxoSmithKline, US Value, Evidence and Outcomes, Research Triangle Park, NC, ²GlaxoSmithKline, US Medical Affairs and Immuno-inflammation, Durham, NC, ³GlaxoSmithKline, US Value, Evidence and Outcomes, Cincinnati, OH, ⁴Groupe d’analyse, Montréal, QC, Canada, ⁵Analysis Group Inc, Boston, MA
Background/Purpose: The aim of this study was to evaluate the real-world effectiveness of the disease-modifying treatment belimumab (BEL), comparing the rates of SLE flares among…
Abstract Number: 1199 • ACR Convergence 2022
Validation of New Medication User Definitions in Single-Specialty EHR Data
Jeffrey Curtis¹, Yujie Su², Michael george³, Cassie Clinton², Patrick Stewart⁴, Tim Buekelman⁵ and Fenglong Xie², ¹Division of Clinical Immunology & Rheumatology, University of Alabama at Birmingham, Birmingham, AL, ²University of Alabama at Birmingham, Birmingham, AL, ³UPENN, Philadelphia, PA, ⁴Bendcare, Boca Raton, FL, ⁵FASTER, Hoover, AL
Background/Purpose: New user designs are standard in many pharmacoepidemiology studies, but a first prescription appearance in electronic health record (EHR) data may not always represent…
Abstract Number: 0354 • ACR Convergence 2022
Clinical and Economic Characterization of Systemic Lupus Erythematosus Patients by Cumulative Corticosteroid Dose over 1 Year: Real-World Observation of Commercially Insured Adults in the United States
Sandra Sze-jung Wu¹, Allison Perry², Helen Varker³, Rich Bizier³, Liisa Palmer³ and Gary Bryant⁴, ¹AstraZeneca, Hockessin, DE, ²IBM Watson Health, New York, NY, ³Merative, Cambridge, MA, ⁴AstraZeneca, New Castle, DE
Background/Purpose: Systemic lupus erythematosus (SLE) is a complex, heterogeneous disease associated with periods of flares. Identifying patients at risk of severe disease and associated resource…
Abstract Number: 1378 • ACR Convergence 2022
Childhood-onset Systemic Lupus Erythematosus: Long-term Outcomes in a Large Multi-ethnic Ontario Cohort
Ha-Seul Jeoung¹, Kuan Liu¹, Roberta Berard², Wes Fidler³, Janet Pope⁴, Johannes Roth⁵, Carter Thorne⁶, Earl Silverman⁷ and Deborah Levy⁸, ¹University of Toronto, Toronto, ON, Canada, ²London Health Sciences Centre, London, ON, Canada, ³St. Joseph's Hospital, Thunder Bay, ON, Canada, ⁴University of Western Ontario, London, ON, Canada, ⁵University of Ottawa, Ottawa, Canada, ⁶Southlake Regional Health Centre, Newmarket, ON, Canada, ⁷The Hospital for Sick Children and University of Toronto, Toronto, ON, Canada, ⁸Division of Rheumatology, The Hospital for Sick Children; Child Health Evaluative Services, SickKids Research Institute; Department of Paediatrics, University of Toronto, Toronto, ON, Canada
Background/Purpose: The long-term morbidity and mortality of childhood-onset SLE (cSLE) after transition to adult care is not well documented. The present study aims to fill…
Abstract Number: 0550 • ACR Convergence 2022
Improving the Accuracy of Automated Gout Flare Ascertainment Using Natural Language Processing of Medical Records and Linked Medicare Claims Data for Real-world Comparative Effectiveness Research
Kazuki Yoshida, Tianrun Cai, Lily G Bessette, Erin Kim, Su Been Lee, Luke E Zabotka, Alec Sun, Julianna M. Mastrorilli, Theresa A. Oduol, Jun Liu, Daniel Solomon, Katherine Liao and Seoyoung Kim, Brigham and Women's Hospital, Boston, MA
Background/Purpose: Gout flares are challenging to study using large real-world data because flares are episodic with varying severity and clinical manifestations. Furthermore, there is no…
Abstract Number: 1488 • ACR Convergence 2022
Incremental Healthcare Resource Utilization and Costs of Herpes Zoster in Patients with Psoriatic Arthritis: A Retrospective Cohort Study
David Singer¹, Philippe Thompson-Leduc², Siyu Ma³, Deepshekhar Gupta⁴, Wendy Cheng⁵, Selvam Sendhil⁶, Manasvi Sundar⁶, Ella Hagopian⁵, Mei Sheng Duh⁷ and Sara Poston¹, ¹GSK, Philadelphia, PA, ²Analysis Group, Inc., Montréal, QC, Canada, ³GSK/Tufts Medical Center, Boston, MA, ⁴Analysis Group, Inc., Menlo Park, CA, ⁵Analysis Group, Inc., Boston, MA, ⁶Analysis Group, Inc., Los Angeles, CA, ⁷Analysis Group Inc, Boston, MA
Background/Purpose: Patients with psoriatic arthritis (PsA) may be at increased risk of herpes zoster (HZ). HZ can involve a painful dermatomal rash and lead to…
Abstract Number: 0707 • ACR Convergence 2022
Accuracy of Administrative Claims Prescription Fill Data to Estimate Glucocorticoid Use and Dose in Patients with Rheumatoid Arthritis
Rachel W. Galvao¹, Jeffrey Curtis², Leslie Harrold³, Qufei Wu⁴, Fenglong Xie⁵ and Michael George⁴, ¹Yale University, New Haven, CT, ²University of Alabama at Birmingham, Hoover, AL, ³CorEvitas, LLC, Waltham, MA, ⁴University of Pennsylvania, Philadelphia, PA, ⁵University of Alabama at Birmingham, Birmingham, AL
Background/Purpose: Glucocorticoids (GCs) are used commonly to treat patients with rheumatoid arthritis (RA) and other inflammatory conditions. As clinical trials are often underpowered to assess…
Abstract Number: 1591 • ACR Convergence 2022
Overall and Post-vaccination Prevalence of Severe COVID-19-related Events Among Commercially Insured Patients with Systemic Lupus Erythematosus and the General U.S. Population
Sandra Sze-jung Wu¹, Gelareh Atefi², Meghan Moynihan³, Kristin Evans³, Liisa Palmer³, Michael Pollack², Christine Dube⁴ and Cassandra Calabrese⁵, ¹AstraZeneca, Hockessin, DE, ²AstraZeneca, Wilmington, DE, ³Merative, Cambridge, MA, ⁴AstraZeneca, Torrington, CT, ⁵Cleveland Clinic Foundation, Cleveland Heights, OH
Background/Purpose: To assess the prevalence of severe COVID-19 (COVID) overall and following vaccination among patients with systemic lupus erythematosus (SLE) and the general population, and…
Abstract Number: 0708 • ACR Convergence 2022
The Impact of Early Antimalarial Adherence on Future Acute Care Utilization Among Rheumatoid Arthritis and Systemic Lupus Erythematosus Patients: A Population-based Study
Md Rashedul Hoque¹, J. Antonio Avina-Zubieta², Diane Lacaille², Mary De Vera³, Yi Qian³, John Esdaile⁴ and Hui Xie⁵, ¹Faculty of Health Sciences, Simon Fraser University, Burnaby, BC, Canada, ²Arthritis Research Canada, University of British Columbia, Vancouver, BC, Canada, ³University of British Columbia, Vancouver, BC, Canada, ⁴Arthritis Research Canada, Vancouver, BC, Canada, ⁵Simon Fraser University, Vancouver, BC, Canada
Background/Purpose: To examine the association between antimalarial (AM) adherence and acute care utilization among newly diagnosed rheumatoid arthritis (RA) and systemic lupus erythematosus (SLE) patients.Methods:…
Abstract Number: 1635 • ACR Convergence 2022
Safety Profile of Hydroxychloroquine in a Large Cohort of Rheumatology Patients Within the US Department of Defense Military Healthcare System
Toni Rush¹, Rachel Robbins², Angelique Collamer² and Jess Edison³, ¹Health Research Tx, Trevose, PA, ²Walter Reed National Military Medical Center, Bethesda, MD, ³Uniformed Services University of the Health Sciences / National Capital Consortium- Walter Reed Bethesda, Bethesda, MD
Background/Purpose: Hydroxychloroquine (HCQ) is a well-established conventional synthetic DMARD for many rheumatologic conditions. While generally believed to be safe, HCQ use is associated with a…
Abstract Number: 0713 • ACR Convergence 2022
The Epidemiology, Clinical Outcomes, and Healthcare Resource Utilization of IgG4-Related Disease Among Commercially Insured People in the United States
Zachary Wallace¹, Gandarvaka Miles², Ekaterina Smolkina³, Natalia Petruski-Ivleva², Duane Madziva², Claire Cook¹, Xiaoqing Fu¹, yuqing zhang⁴, John Stone⁵ and Hyon Choi⁶, ¹Massachusetts General Hospital, Boston, MA, ²Sanofi, Unknown, ³Sanofi, Amsterdam, Netherlands, ⁴Massachusetts General Hospital, Quincy, MA, ⁵Massachusetts General Hospital Rheumatology Unit, Harvard Medical School, Boston, MA, ⁶MASSACHUSETTS GENERAL HOSPITAL, Lexington, MA
Background/Purpose: IgG4-related disease (IgG4-RD) is an immune-mediated condition that causes fibroinflammatory lesions, often presenting as pancreatitis, cholangitis, sialoadenitis, and retroperitoneal fibrosis. The epidemiology of IgG4-RD,…
Abstract Number: 1978 • ACR Convergence 2022
Using Administrative Health Data to Construct a Frailty Index as a Measure of Susceptibility to Adverse Health Outcomes Among Individuals with Rheumatoid Arthritis
Alexandra Legge¹ and Diane Lacaille², ¹Arthritis Research Canada, Dalhousie University, Halifax, NS, Canada, ²Arthritis Research Canada, University of British Columbia, Vancouver, BC, Canada
Background/Purpose: Frailty is increasingly recognized among individuals living with RA. While several tools are available to assess frailty in clinical settings, it is less readily…
Abstract Number: 0065 • ACR Convergence 2022
Rheumatoid Arthritis Clinical Care Pathway Implementation: A Step Towards Improved Outcomes and Value-Based Care
Tarun Sharma¹, paul lebovitz¹, chetan rajput², Lori Mcaninch³, ellen Kraemer³, izabela Stanescu³, adam dore¹, joseph ahearn³ and Susan Manzi⁴, ¹Allegheny Health Network, Pittsburgh, PA, ²Highmark Health, Pittsburgh, ³Allegheny Health Network, Pittsburgh, ⁴Allegheny Health Network, Lupus Center of Excellence, Wexford, PA
Background/Purpose: Care transformation in a chronic illness like RA requires delivery of health care services through a patient-centric care model. Within an integrated delivery and…

« Previous Page
1
…
6
7
8
9
10
…
13
Next Page »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].